Tuncer Feyza Nur, Çiftçi Doğanşen Sema, Serbest Esin, Tanrıkulu Seher, Ekici Yeliz, Bilgiç Bilge, Yarman Sema
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Genet Test Mol Biomarkers. 2018 Dec;22(12):702-708. doi: 10.1089/gtmb.2018.0133. Epub 2018 Nov 21.
Aryl hydrocarbon receptor-interacting protein () gene mutations have long been associated with apparently sporadic pituitary adenomas (PAs) with a prevalence range of 0-12%. The aim of this study was to evaluate the frequency of germline variations in a large cohort of apparently sporadic PAs diagnosed before the age of 40 years, who did not exhibit hypercalcemia and/or MEN1 syndrome components during long-term follow-up. A total of 97 patients, diagnosed with functional PAs ≤40 years old, composed of somatotropinoma ( = 55), prolactinoma ( = 25), and corticotrophinoma ( = 17), were recruited for this study. Fifty-one of these patients [somatotropinoma ( = 30), prolactinoma ( = 15), and corticotrophinoma ( = 11)] were previously reported as mutation-negative by Sanger sequencing. The entire coding sequence of the gene, along with exon/intron boundaries and the untranslated regions of 41 newly recruited patients, were sequenced for germline variations. In addition, all patients were subjected to multiplex ligation-dependent probe amplification to detect copy number variations in the gene. The c.911G>A: p.Arg304Gln (rs104894190) variant was detected in only two patients with functional PA: one with somatotropinoma [in 1/55 (1.8%)] and one with prolactinoma [in 1/25 (4%)]. None of the corticotrophinomas revealed gene alterations. Thus, the overall prevalence of variation was 2.1% in our cohort. Germline gene variations among Turkish patients with apparently sporadic PAs are relatively rare among patients ≤40 years old. None of the patients in our cohort revealed any obviously pathogenic variants.
芳烃受体相互作用蛋白()基因突变长期以来一直与明显散发的垂体腺瘤(PA)相关,其患病率在0%至12%之间。本研究的目的是评估一大群40岁之前诊断为明显散发PA且在长期随访中未出现高钙血症和/或MEN1综合征成分的患者中种系变异的频率。本研究共纳入了97例诊断为功能性PA且年龄≤40岁的患者,包括生长激素瘤(=55例)、催乳素瘤(=25例)和促肾上腺皮质激素瘤(=17例)。其中51例患者[生长激素瘤(=30例)、催乳素瘤(=15例)和促肾上腺皮质激素瘤(=11例)]之前经桑格测序报告为突变阴性。对41例新纳入患者的基因整个编码序列以及外显子/内含子边界和非翻译区进行种系变异测序。此外,所有患者均接受多重连接依赖探针扩增以检测该基因的拷贝数变异。仅在2例功能性PA患者中检测到基因c.911G>A:p.Arg304Gln(rs104894190)变异:1例生长激素瘤患者[在1/55(1.8%)中]和1例催乳素瘤患者[在1/25(4%)中]。所有促肾上腺皮质激素瘤均未发现基因改变。因此,我们队列中变异的总体患病率为2.1%。在40岁以下明显散发PA的土耳其患者中,种系基因变异相对罕见。我们队列中的患者均未发现任何明显致病性变异。